ATTD 2011 Year Book

The traditional agents for controlling the levels of glucose in theblood remain important therapies but they have their downside fromthe point of view of tolerability and side effects. Moreover, theyappear not to be able to counter the natural history deteriorationof the disease in terms of the onset of diabetic-relatedcomplications.
Recent years have seen an influx of new treatment therapies andtechnologies aimed at achieving better glycaemic control fordiabetic patients such as liraglutide (Novo Nordisk) andsaxagliptin (BMS/Astra-Zeneca) and insulin pumps, away from themore traditional therapies used (classic insulin therapy, oralhypoglycaemics).
This book outlines these new technologies/treatments bycollating the best journal articles published in the last year, andproviding expert analysis on each one.
Advanced Technologies and Treatment for Diabetes 3E bringstogether and critically analyses the last year's mostimportant articles published in the world's leading medicaljournals on this topic. Chapters are focused on the most currenthot topic areas such as: new methods of insulin delivery; internetand IT use in treatment of diabetes; bariatric surgery &diabetes; and immunotherapy for type 1 diabetes.
Each chapter includes abstracts of the published articles,scientific conclusions made, as well as annotations and a commentsand analysis section from the relevant chapter editor, each ofwhich being a well-known expert in the field.
All researchers in the fields of diabetes, endocrinology andmetabolism will find this book extremely useful, as will diabetestechnology developers, and specialist endocrinologists involvedwith the care of diabetic patients.